All In Biotech

Drug Trial Radar · NCT02002650

Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Routine Rectal Indomethacin Given Before Procedure Reduced Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jun 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,600

Actual

Start

Dec 2013

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
Air Force Military Medical University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 6, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. However, the risk factors of PEP is not fully clear. Rectal indomethacin before ERCP for all patients, not just for selected high-risk patients, may preventing PEP maximum. The purpose of this study is to determine whether routine using of rectal indomethacin is more effective than the conditional strategy.

Conditions

  • Post-ERCP Acute Pancreatitis

Interventions

  • Pre-ERCP rectal IndomethacinDrug

    Rectal Indomethacin was administrated within 30min before ERCP in all patients.

  • Post-operational Rectal IndomethacinDrug

    Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-ERCP PancreatitisTime frame: 30 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • General Hospital of NingXia Medical University

    Yinchuan, Ningxia, China

  • Xijing Hospital of Digestive Diseases

    Xi'an, Shaanxi, China

  • No. 451 Hospital

    Xi'an, Shaanxi, China

  • The First Affiliated Hospital Of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Urumqi General Hospital of Lanzhou Military Region

    Ürümqi, Xinjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.